FDA Staff Reviewers Say Treatment With Geron's Anemia Drug Imetelstat Is Associated With Risks That Might Be Considered Substantial; It Is Not Clear That Risks Of Treatment With Imetelstat Are Outweighed By The Potential Benefit For The Intended Population; The Patient-Reported Outcomes Are Not Supportive Of Geron's Treatment Effect